Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Zoetis logoZoetis ZTS

The company said it declared a dividend of $0.432 per share for Q3 2024, payable on May 22, 2024. The press release said the Board of Directors declared the dividend.

8-KRegulation FD DisclosureFiled Period of report Summary published (UTC)

Key points

AI summary
  1. The company said it declared a dividend of $0.432 per share for Q3 2024, payable on May 22, 2024. The press release said the Board of Directors declared the dividend.

  2. The company said the dividend will be paid on September 4, 2024 to holders of record of its common stock as of the close of business on July 18, 2024.

  3. The company said in its press release that Zoetis generated revenue of $8.5 billion in 2023, with approximately 14,100 employees, and that it operates in more than 100 countries with its medicines, vaccines, diagnostics and other products and technologies.

  4. The company said the information in Item 7.01 and Exhibit 99.1 (press release dated May 22, 2024) shall not be deemed "filed" under the Securities Exchange Act of 1934.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Zoetis Declares Q3 2024 Dividend

The company said it declared a dividend of $0.432 per share for Q3 2024, payable on May 22, 2024. The press release said the Board of Directors declared the dividend.

Source · Based on the filing body and exhibits

Dividend Payment and Record Date

The company said the dividend will be paid on September 4, 2024 to holders of record of its common stock as of the close of business on July 18, 2024.

Source · Based on the filing body and exhibits

Company Overview in the Press Release

The company said in its press release that Zoetis generated revenue of $8.5 billion in 2023, with approximately 14,100 employees, and that it operates in more than 100 countries with its medicines, vaccines, diagnostics and other products and technologies.

Source · Based on the filing body and exhibits

Item 7.01 Disclosure and Attached Press Release

The company said the information in Item 7.01 and Exhibit 99.1 (press release dated May 22, 2024) shall not be deemed "filed" under the Securities Exchange Act of 1934.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.